Cargando…
Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre‐specified analysis of the Chinese population from the BERSON clinical trial
AIM: The aim of this study was to evaluate the efficacy and safety of evolocumab with background atorvastatin in Chinese patients with type 2 diabetes mellitus (T2DM) and hyperlipidaemia or mixed dyslipidaemia. MATERIALS AND METHODS: This is a pre‐specified analysis of patients in the BERSON study (...
Autores principales: | Chen, Yundai, Yuan, Zuyi, Lu, Juming, Eliaschewitz, Freddy G., Lorenzatti, Alberto J., Monsalvo, Maria Laura, Wang, Nan, Hamer, Andrew W., Ge, Junbo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594089/ https://www.ncbi.nlm.nih.gov/pubmed/30851062 http://dx.doi.org/10.1111/dom.13700 |
Ejemplares similares
-
Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial
por: Lorenzatti, Alberto J., et al.
Publicado: (2019) -
Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON
por: Lorenzatti, Alberto J., et al.
Publicado: (2021) -
Effects of evolocumab therapy and low LDL‐C levels on vitamin E and steroid hormones in Chinese and global patients with type 2 diabetes
por: Blom, Dirk J., et al.
Publicado: (2020) -
New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
por: Lorenzatti, Alberto J, et al.
Publicado: (2020) -
Statin Therapy and the Assessment of Hepatoprotection in Patients with Dyslipidaemia
por: Beznă, Marinela, et al.
Publicado: (2023)